Following approval this year by the US Food and Drug Administration (FDA) of the Treo abdominal aortic stent-graft system for the treatment of patients with abdominal aortic aneurysms (AAA), Terumo Aortic has announced the commercial launch of this endovascular device.
One of the first procedures was undertaken by Matt Eagleton (Massachusetts General Hospital, Boston, USA). Eagleton comments: “The procedure was very successful, and the patient is recovering well. As the national principal investigator of the investigational device exemption (IDE) study, I was impressed with the performance of the Treo stent-graft system. Stent migration and endoleaks are major concerns in endovascular aortic repair (EVAR), and as the Treo device offers both suprarenal and infrarenal fixation, distributing the stent-graft fixation in two different anatomical levels, this may work to reduce potential migration as evidenced in the pivotal study. Furthermore, the device design leads to clinically meaningful aneurysm sac shrinkage.”
Treo received CE mark approval in 2015, and is integral to Terumo Aortic’s market-leading portfolio of surgical, endovascular, and hybrid devices to treat every segment of the aorta.
